Skip to main content

Table 13 Total economic benefits of influenza immunisation in the school-age population, sensitivity analysis

From: Influenza in the school-aged population in Mexico: burden of disease and cost-effectiveness of vaccination in children

Influenza-associated costsBase caseConservativeOptimistic
Vaccination coverage50%30%70%
Vaccine effectiveness50%19%68%
Direct Costs
 Laboratory diagnosis−13,270,647−3,025,707−25,267,311
 Medical consultations−14,578,525−3,323,904−27,757,511
 Drugs−2,589,893−590,496−4,931,157
 Hospitalisations−93,511,195−21,320,552− 178,045,314
 Influenza immunisation of the school-aged population27,421,60216,452,96138,390,243
 Total direct costs (Third-Party Payer perspective)−96,528,657−11,807,698− 197,611,050
Indirect costs
 Productivity loss−14,431,429−3,290,366−27,477,440
 Premature death−1,029,382−234,699−1,959,943
 Total indirect costs−15,460,811−3,525,065−29,437,384
Total cost of influenza−111,989,467−15,332,762−227,048,433